The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
Official Title: A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
Study ID: NCT04845139
Brief Summary: The purpose of this study is to determine whether Nivolumab given intrathecally is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Detailed Description: This is a case study aiming to recruit 1 patient. This study is indicated for relapsed/refractory primary central nervous system lymphoma. Primary objective is to explore the safety.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Jianmin Zhang, Hangzhou, Zhejiang, China
Name: Jianmin Zhang, M.D.
Affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Role: PRINCIPAL_INVESTIGATOR